The FDA has approved Restylane Contour for improvement of temple hollowing, expanding Galderma's indication portfolio beyond the midface and lips. Temple volume loss is a recognized marker of aging and a common off-label injection site; this approval gives practices a cleared product and removes regulatory ambiguity around the indication.
Injectables
FDA Approves Restylane Contour for Temple Hollowing — Galderma Expands Filler Indication Portfolio
Galderma gains clearance for HA filler in temple region, adding a new anatomical indication to its Restylane platform.
Temple hollowing approval removes regulatory ambiguity from a common off-label injection site.
Operationally, this is incremental for Galderma but meaningful for practices: it adds a distinct, billable treatment area to your Restylane menu, supports patient education (you can now cite FDA approval in consultations), and may drive higher per-session syringe consumption in comprehensive facial rejuvenation plans. Like Skinvive's neck approval, this reflects the industry trend of expanding filler indications beyond traditional zones — practices should expect similar approvals from AbbVie and Evolus as manufacturers seek to differentiate and defend market share.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.